Valuation: ACLS THER

Market Cap 795M 693M 654M 594M 1.11B 76.27B 1.12B 7.84B 3.03B 38.78B 2.99B 2.92B 125B P/E 2026 *
-8.51x
P/E 2027 * -6.99x
Enterprise Value 642M 560M 528M 480M 899M 61.58B 903M 6.33B 2.44B 31.31B 2.41B 2.36B 101B EV / Sales 2026 *
101x
EV / Sales 2027 * 121x
Free-Float
97.82%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-01-16
Director of Finance/CFO 39 2022-12-31
President 67 2024-11-17
Director TitleAgeSince
Chairman 56 2022-12-31
Director/Board Member 50 2014-08-31
Director/Board Member 59 2016-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+1.82%+38.93%+77.73% 62.32B
-3.21%-7.27%-17.73%+351.98% 27.07B
-2.64%-0.69%-0.26%-11.90% 24.78B
+0.71%+8.50%+27.76%-15.29% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.22%+3.99%+44.28%+173.35% 14.49B
+0.73%+1.71%-7.18%+886.19% 14.14B
-0.54%-0.56%+20.59%+224.93% 12.35B
Average -0.71%+1.68%+35.95%+230.88% 29.13B
Weighted average by Cap. -0.59%+1.39%+35.27%+164.84%

Financials

2026 *2027 *
Net sales 6.34M 5.53M 5.22M 4.74M 8.88M 608M 8.92M 62.51M 24.12M 309M 23.81M 23.28M 995M 5.34M 4.65M 4.4M 3.99M 7.48M 512M 7.51M 52.65M 20.32M 260M 20.05M 19.61M 838M
Net income -90.33M -78.77M -74.37M -67.54M -127M -8.67B -127M -891M -344M -4.41B -339M -332M -14.18B -112M -97.96M -92.5M -83.99M -157M -10.78B -158M -1.11B -428M -5.48B -422M -413M -17.63B
Net Debt -153M -134M -126M -114M -214M -14.69B -215M -1.51B -583M -7.47B -575M -562M -24.03B -147M -128M -121M -110M -205M -14.06B -206M -1.45B -558M -7.15B -551M -538M -23B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!